[Dual acting reuptake inhibitors in the treatment of depression and pain].
Pain is a common symptom in many somatic illnesses. Chronic pain can trigger affective disorders and anxiety states. But they can also be symptoms of mental disease, e.g. depression, without somatic cause. For this reason diagnosis of the underlying cause of pain can be very difficult in daily practice. Two neurotransmitters, serotonin and noradrenaline, play an important role not only in the pathophysiology of depression but importantly also as mediators in pain regulation. Thus antidepressants have for a long time been used in the treatment of chronic pain and depression. The newly available duloxetine is a drug with properties of both serotonin and noradrenaline re-uptake inhibition. This drug acts not only as an antidepressant but also reduces pain. It has been approved for the treatment of pain in diabetic neuropathy.
Hajak
G
G
Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie der Universität Regensburg, Regensburg, Germany. goeran.hajak@medbo.de
D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use; D002908:Chronic Disease; D003863:Depression / Q000188:drug therapy* / Q000209:etiology; D048909:Diabetes Complications / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000523:psychology*; D000068736:Duloxetine Hydrochloride; D006801:Humans; D009638:Norepinephrine / Q000378:metabolism; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D012701:Serotonin / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use*; D016896:Treatment Outcome
D018759:Adrenergic Uptake Inhibitors; D000928:Antidepressive Agents; D000068736:Duloxetine Hydrochloride; D009638:Norepinephrine; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors; D013876:Thiophenes